20
Chongqing Daxin Pharmaceutical Co Ltd, based in China, is a pharmaceutical company that stands out with its certifications from FDA.
One of their notable products is TOBRAMYCIN USP, with a corresponding US DMF Number 13774.
Remarkably, this DMF maintains an Active status since its submission on September 01, 1998, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of April 02, 2013, and payment made on March 26, 2013, indicating their dedication to facilitating drug approvals, Categorized as Type II